Sana Biotechnology’s (SANA) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Sana Biotechnology (NASDAQ:SANA) in a research report report published on Tuesday morning,Benzinga reports. The brokerage currently has a $11.00 target price on the stock. HC Wainwright also issued estimates for Sana Biotechnology’s Q1 2025 earnings at ($0.24) EPS, Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($0.97) EPS, FY2026 earnings at ($0.95) EPS, FY2027 earnings at ($0.89) EPS, FY2028 earnings at ($0.77) EPS and FY2029 earnings at ($0.59) EPS.

SANA has been the topic of a number of other reports. TD Cowen raised Sana Biotechnology from a “hold” rating to a “buy” rating in a research report on Wednesday, January 8th. Citizens Jmp upgraded Sana Biotechnology from a “market perform” rating to an “outperform” rating and set a $5.00 price objective for the company in a research report on Tuesday. Finally, Jefferies Financial Group started coverage on Sana Biotechnology in a report on Friday, March 14th. They set a “buy” rating and a $7.00 target price on the stock. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $10.80.

Sana Biotechnology Trading Down 3.4 %

Shares of SANA stock opened at $2.26 on Tuesday. The company has a market cap of $504.59 million, a price-to-earnings ratio of -1.61 and a beta of 1.63. The stock has a 50 day simple moving average of $2.98 and a 200-day simple moving average of $3.19. Sana Biotechnology has a 12-month low of $1.52 and a 12-month high of $10.50.

Sana Biotechnology (NASDAQ:SANA) last released its quarterly earnings data on Monday, March 17th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.02. On average, equities analysts forecast that Sana Biotechnology will post -1.16 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Sana Biotechnology news, insider Fmr Llc sold 290,912 shares of the company’s stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $6.49, for a total value of $1,888,018.88. Following the transaction, the insider now owns 4,541,511 shares of the company’s stock, valued at approximately $29,474,406.39. This represents a 6.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 31.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. FMR LLC increased its holdings in shares of Sana Biotechnology by 16.3% in the third quarter. FMR LLC now owns 31,609,175 shares of the company’s stock valued at $131,494,000 after buying an additional 4,438,949 shares in the last quarter. State Street Corp grew its position in Sana Biotechnology by 4.2% during the 3rd quarter. State Street Corp now owns 6,627,320 shares of the company’s stock worth $27,570,000 after purchasing an additional 269,274 shares in the last quarter. Geode Capital Management LLC grew its position in Sana Biotechnology by 0.8% during the 4th quarter. Geode Capital Management LLC now owns 3,193,081 shares of the company’s stock worth $5,206,000 after purchasing an additional 26,601 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in Sana Biotechnology by 7.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,108,617 shares of the company’s stock worth $5,068,000 after purchasing an additional 219,498 shares in the last quarter. Finally, Integral Health Asset Management LLC grew its position in Sana Biotechnology by 11.1% during the 4th quarter. Integral Health Asset Management LLC now owns 2,000,000 shares of the company’s stock worth $3,260,000 after purchasing an additional 200,000 shares in the last quarter. Institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.